Skip to main content
Clinical Trials/NCT04976790
NCT04976790
Unknown
N/A

Effectiveness, Safety and Economic Evaluation of Chinese Tuina (Chinese Massage and Flurbiprofen Cataplasms) in the Treatment of Chronic Nonspecific Low Back Pain

Beijing University of Chinese Medicine1 site in 1 country90 target enrollmentOctober 28, 2021

Overview

Phase
N/A
Intervention
Chinese Tuina therapy
Conditions
Chronic Nonspecific Low Back Pain
Sponsor
Beijing University of Chinese Medicine
Enrollment
90
Locations
1
Primary Endpoint
Changes in NRS scores for pain intensity
Last Updated
4 years ago

Overview

Brief Summary

Chronic Nonspecific Low back Pain (NLBP) is a common symptom in today's society. It causes serious health and economic burdens. Low back pain can be attributed to excessive physical exertion or trauma, resulting in damage or degradation of the vertebrae, intervertebral discs, or spinal muscles and nonspecific low back pain typically can account for 90% of the patients with 35 to 55 years old. Some guidelines endorse the cautious use of medication and surgery and take nonpharmacological and noninvasive treatments as a first-line treatment, including routine health education, exercise, psychotherapy, and physical therapies, owing to the risk of trauma and the cost. With a long history, Tuina is a one of the common nonsurgical methods to treat LBP in China.. The effect of Tuina is attributed to relaxing muscles and tendons, improving circulation, regulating spinal balance, decreasing edema and aseptic inflammation. Many clinical reports have confirmed its effectiveness, but more clinical trials are required to provide evidence of Tuina for low back pain. Therefore, this study was designed to compare the effectiveness of Tuina with Flurbiprofen Cataplasms for patients with low back pain on the basis treatment of health education and self-management exercise at home.

Detailed Description

This study is a single-center, assessor- and analyst-blinded randomized controlled trial conducted in Beijing, China, at Dongzhimen hospital affiliated to Beijing university of Chinese medicine. In total, 90 patients will be recruited and randomly assigned to a Tuina group and a Flurbiprofen Cataplasms group in a 1:1 ratio. The Chinese Tuina group will be given twice per week for 14 days, and medicine group will be given Flurbiprofen Cataplasms twice daily for 14 days. We will ask some researchers who are blinded to assignment to accomplish the outcome assignment and statistical analyses independently. The outcome will be measured by three self-report questionnaires, which can reflect the lumbar dysfunction, pain, quality of life, and adverse events. Four time points will be used to assess outcomes, including baseline, 7 days, 14 days and 28 days after randomization.

Registry
clinicaltrials.gov
Start Date
October 28, 2021
End Date
May 15, 2022
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Beijing University of Chinese Medicine
Responsible Party
Principal Investigator
Principal Investigator

Changhe Yu

Clinical professor

Beijing University of Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of non-specific low back pain;
  • Aged between 18 and 65,male and female;
  • Duration of low back pain as the main symptom for at least 12 weeks;
  • pain intensity with NRS score equals or more than 4;
  • X-ray or CT on low back helped to confirm no lumbar diseases;
  • Ability to understand and complete the questionnaires;
  • Any treatments aiming to CNLBP need more than 1 month washout period;
  • Volunteer to participate in the study and informed consent form.

Exclusion Criteria

  • Sciatica, myelopathy, displacement, or radiculopathy due to lumbar intervertebral disc disorders or Spondylolisthesis;
  • Chronic low back pain caused by local disease (e.g., lumbar fracture, lumbar tumor, lumbar tuberculosis, lumbar spine surgery or trauma);
  • Immune diseases such as rheumatoid joints and ankylosing spondylitis;
  • Severe primary disease such as cardiovascular, lung, kidney, and hematopoietic disease;
  • Pregnant or lactating women;
  • patients with skin injury;
  • Allergy or intolerance to Non-steroidal anti-inflammatory drug (e.g., asthma, gastrointestinal ulcers, and bleeding);
  • Mental illness;
  • Poor compliance of examination and treatment.

Arms & Interventions

Chinese Tuina group (CTG)

The participants in Chinese Tuina group will receive the traditional Chinese Tuina therapy on the basis of health education and home-exercise. All the treatment will cost 20-25 minutes. Patients in this group received 4 treatments over 14 days.

Intervention: Chinese Tuina therapy

Flurbiprofen Cataplasms group (FCG)

The FCG group received flurbiprofen gel on the basis of the health education and home-exercise, twice daily, for 14 days.

Intervention: Flurbiprofen Cataplasms group (FCG).

Outcomes

Primary Outcomes

Changes in NRS scores for pain intensity

Time Frame: Change from baseline at 14 days

The changes in NRS scores at 14 days after randomization.

Secondary Outcomes

  • Changes in 7-level Likert Scale for patient assessment global improvement(Change from baseline at 7 days,14 days and 28 days after randomization)
  • Changes in PROMIS® Item Bank v2.0-Physical Function scores for Physical Function(Change from baseline at 14 days after randomization)
  • Incremental cost-effectiveness ratio and Incremental cost-utility ratio(Change from baseline at 7 days,14 days and 28 days after randomization)
  • Changes in the ODI scores for lumbar function(Change from baseline at 7 days,14 days and 28 days after randomization)
  • Clinical effective rate(Change from baseline at 7days,14days and 28 days after randomization)
  • Changes in the Quebec Low Back Pain Disability Scale scores for lumbar function(Change from baseline at 14 days after randomization)
  • Incidence of adverse events(Change from baseline at 7 days,14 days and 28 days after randomization)
  • Cost-utility analysis (CUA) ratio(Change from baseline at 7 days,14 days and 28 days after randomization)
  • Changes in Quality adjusted life years (QALY)(Change from baseline at 7 days,14 days and 28 days after randomization)
  • Changes in NRS scores for pain intensity(Change from baseline at 7 days and 28 days after randomization)
  • Changes in PROMIS® Scale v1.2 Scale for patient assessment global improvement(Change from baseline at 14 days after randomization)
  • Cost-Effectiveness Analysis (CEA) ratio(Change from baseline at 7 days,14 days and 28 days after randomization)

Study Sites (1)

Loading locations...

Similar Trials